文献速递流行病学与生物统计临床试验与 GCP

优化针对卒中患者的贝叶斯分层自适应平台试验设计

Optimizing a Bayesian hierarchical adaptive platform trial design for stroke patients.
PubMed 文献 · Trials · 2022-09-06

本文提出一种基于β-二项模型的贝叶斯平台试验设计,用于二分类结局,采用治疗臂内亚组分层建模借信息、响应自适应随机化(RAR)平衡统计功效与患者获益、以及时间漂移调整三种策略。以缺血性卒中患者亚组治疗选择为动机开展广泛模拟研究,结果显示该设计获得高统计功效和良好患者获益,且对人群漂移稳健。

要点

  • 设计采用亚组分层建模借信息、响应自适应随机化及时间漂移调整三种策略。
  • 模拟研究显示该设计获得高统计功效和良好患者获益,且对人群漂移稳健。
  • 该设计在传统响应自适应随机化与固定1:1分配的优势之间取得良好平衡。

核心结论

  • 所提出的方法获得高统计功效和良好患者获益,且对时间上的人群漂移稳健。
  • 该设计在传统响应自适应随机化方案与固定1:1分配的优势之间提供了良好平衡,可能成为研究多个亚组的二分类结局试验的有前景选择。

研究设计与样本

  • 基于β-二项模型的贝叶斯平台试验设计,用于二分类结局。
  • 采用三种关键策略:治疗臂内亚组分层建模以跨亚组借信息、响应自适应随机化(RAR)方案、以及时间潜在漂移调整。
  • 以一项旨在为缺血性卒中患者不同亚组人群寻找适当治疗的拟议临床试验为动机,开展广泛模拟研究以验证方法、比较不同分配规则并研究模型操作特征。

主要发现

  • 所提出的方法获得高统计功效和良好患者获益。
  • 该设计对时间上的人群漂移稳健。
  • 该设计在传统响应自适应随机化方案与固定1:1分配的优势之间提供了良好平衡。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Platform trials are well-known for their ability to investigate multiple arms on heterogeneous patient populations and their flexibility to add/drop treatment arms due to efficacy/lack of efficacy. Because of their complexity, it is important to develop highly optimized, transparent, and rigorous designs that are cost-efficient, offer high statistical power, maximize patient benefit, and are robust to changes over time. METHODS: To address these needs, we present a Bayesian platform trial design based on a beta-binomial model for binary outcomes that uses three key strategies: (1) hierarchical modeling of subgroups within treatment arms that allows for borrowing of information across subgroups, (2) utilization of response-adaptive randomization (RAR) schemes that seek a tradeoff between statistical power and patient benefit, and (3) adjustment for potential drift over time. Motivated by a proposed clinical trial that aims to find the appropriate treatment for different subgroup populations of ischemic stroke patients, extensive simulation studies were performed to validate the approach, compare different allocation rules, and study the model operating characteristics. RESULTS AND CONCLUSIONS: Our proposed approach achieved high statistical power and good patient benefit and was also robust against population drift over time. Our design provided a good balance between the strengths of both the traditional RAR scheme and fixed 1:1 allocation and may be a promising choice for dichotomous outcomes trials investigating multiple subgroups.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gao G, Gajewski BJ, Wick J, et al. Optimizing a Bayesian hierarchical adaptive platform trial design for stroke patients. Trials. 2022. PMID: 36068547. doi:10.1186/s13063-022-06664-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。